What's new

Imagion Biosystems establishes collaboration with Siemens Healthineers

(May 21, 2020) Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to further explore the utility of Imagion’s MagSense™ nanoparticles as an MRI contrast agent.

The collaboration will see Siemens Healthineers work with Imagion to identify optimal MRI scanning protocols for the MagSense™ HER2 targeted nanoparticles. Siemens Healthineers in-kind contribution of expertise and provision of technical support to clinical sites will be valuable should Imagion undertake a study in Australia which includes MRI scans.

Imagion has previously announced that it is planning for its first clinical study of the MagSense™ technology in HER2 breast cancer patients. The MagSense™ nanoparticles are designed to be detectable only when attached to cancer cells providing a specific means of cancer imaging, and has a received Breakthrough Device designation from the US Food and Drug Administration (FDA). The collaboration with Siemens is in line with Imagion’s strategy to explore an additional and alternative use of the MagSense™ nanoparticles as an MRI contrast agent.

Imagion Biosystems presented its first data showing that the MagSense™ nanoparticles could be used as a magnetic resonance imaging agent, at the World Molecular Imaging Conference in September 2019. This collaboration establishes a path for Imagion to further explore MRI as a commercial pathway leveraging the large global installed base of existing MRI scanners.

Contrast agents are used to enhance the image and improve resolution. To-date, imaging agents have been general purpose, creating contrast at tissue boundaries but not providing functional imaging utility. A targeted MagSense™ nanoparticle could be used as a contrast agent to enhance an MR image of specific diseased tissue, thus providing a clear and accurate method to use imaging to non-invasively detect cancer with existing imaging technology.

“We are very pleased to have Siemens Healthineers offer of assistance as we look at all the possibilities to develop and commercialize our technology,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “The ability to use a targeted contrast agent like ours, in the MRI setting, could transform the way MRI is used to diagnose cancer and other diseases. In entering into this collaboration, we will jointly gain insight into the clinical and commercial potential of our novel technology. We are proud that Imagion continues to attract the support of leading industry players and opinion leaders.”

“Siemens Healthineers has a strong focus on expanding Precision Medicine and transforming care delivery,” said Dr Kieran O’Brien, Head of Collaborations and Research for Australia and New Zealand for Siemens Healthcare Pty Ltd, “Imagion’s targeted contrast technology MagSense™ could offer patients a more specific means to monitor cancer with MRI, and we look forward to assisting Imagion in investigating the application of their technology with MRI scanners.”

Siemens Healthineers is a leading medical technology company. With over 120 years of experience, Siemens Healthineers is enabling healthcare providers to increase their value through digitalised healthcare. Siemens Healthineers portfolio of products and services is largely compromised of its core areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine.

Robert Proulx from Imagion Biosystems (IBX) | CEO Masterclass

(March 26, 2020) Peter Switzer is joined by the CEO of medical imaging company Imagion Biosystems (IBX), Robert Proulx.

Imagion Biosystems launches its fresh new website

(February 13, 2020) Imagion has transformed dramatically since our establishment in 2016, and so it comes as no surprise that our website needs to evolve with us.

As we advance toward our first-in-human study of our MagSense technology for the detection and staging of HER2 metastatic breast cancer, this new website will more effectively tell Imagion’s story, and will allow our key stakeholders to come on this journey with us.

Our user-friendly design reflects the innovative company we are today and positions us strongly for the dynamic business we will continue to be. Our investor hub allows investors to stay up-to-date with the latest interviews, ASX news, and presentations.

We encourage you to check out our new website

Imagion Biosystems receives FDA confirmation that breast cancer technology is a breakthrough device

(July 24, 2019) Imagion Biosystems (ASX:IBO) executive chairman Bob Proulx updates Proactive Investors on the company receiving US Food and Drug Administration (FDA) confirmation that its breast cancer detection technology is a breakthrough device.

Magnetic nanoparticles leap from lab bench to breast cancer clinical trials

(April 30, 2018) To listen to the replay of the investor call of June 16, 2017 concerning the Imagion IPO, please follow the link below.

Read the full article at the following link

Conference Call for Imagion Biosystems IPO

(June 19, 2017) To listen to the replay of the investor call of June 16, 2017 concerning the Imagion IPO, please follow the link below.

Listen to the conference call MP3 file

Manhattan Scientifics, General Cable Partner to Develop Nano-structured Wire and Cable Applications

(December 7, 2016) The effort is focused on overhead conductors to reduce line losses in power transmission and distribution. Reprinted courtesy of Wire Journal International.

Read the full article by viewing the following PDF file

Magnetic nanoparticles may reveal early traces of cancer

(April 28, 2016) Nanoscale magnets offer a new way to find faint, early traces of cancer in patients, according to Rice University students working on a method to capitalize on the magnets’ properties.

Read the full article at the following link

5 questions about making millions and fighting cancer for MHTX founder Marvin Maslow

(September 2, 2015) Marvin Maslow may not be as well-known as investors George Soros, Michael Milken or David Bonderman. But one thing he has in common with those marquee names is his goal of bringing experimental cancer-fighting technology to market.

Maslow is the founder and current chairman of Manhattan Scientifics Inc., a New York City company headquartered in the Chrysler Building and trading under the ticker MHTX. The company, a technology incubator that develops medical devices, currently finds itself in growth mode, trading on the OTC Venture Market and not at all shaken by the recent goings-on in the stock market.

Read the full article at the following link

Magnetic Relaxometry Enters the Blogosphere

(July 17, 2015) Pursuing his new and very personal interest in the latest cancer treatments and technologies, Texas blogger and book author Al Petter recently wrote about his opportunity to get a behind-the-scenes look at what is happening at MD Anderson in advanced cancer research. We were surprised and delighted to learn that Mr. Petter was given a personal tour of the Magnetic Relaxometry Lab by Kelsey Mathieu, a lead investigator in our collaboration. Mr. Petter wrote a detailed account of his visit on his blog, "Texas Thru My Back Door." There, Mr. Petter also revealed that his fiancée, Suzanne, is a breast cancer patient and clinical trial participant at MD Anderson.

"Suzanne and I were so impressed by the promise of this new technology, we wanted to help out," wrote Mr. Petter. And so they did. These generous and forward-thinking Texans have establis hed the "Suzanne's Cancer Adventure" GoFundMe campaign to raise funds for magnetic relaxometry research at the MD Anderson Cancer Center.

Read Nanotechnology at MD Anderson Cancer Center at Texas Thru My Back Door.

Suzanne's Cancer Adventure GoFundMe campaign can be found at the following link

100 Times More Sensitive

(June 26, 2015) In a newly released publication, Magnetic Relaxometry has been demonstrated to be more than 100 times more sensitive than previously reported. The optimized method can detect, localize, and quantify cancer cells with sensitivity and precision greatly exceeding alternative methods such as mammography and ultrasound imaging, making it an ideal platform for the in vivo detection of solid tumors.

Download the publication here.

Sneak Peek of New Nano-Particle Lab at Senior Scientific

(June 25, 2015) The New Nano Particle Lab at our Albuquerque facility is almost complete. Click below to see a few photos of the lab.

A Letter from the New President of Senior Scientific LLC

(May 3, 2015) Cancer continues to be one of the leading causes of mortality globally. Despite technical advances in science and medicine made in the last 150 years we still lack effective forms of therapy for many types of cancer, and the general consensus within the medical community is that more lives could be saved if cancer could be detected earlier.

Read the entire letter (PDF)

Sandia Labs recently releases their 2014 "Partnerships" report

(March 27, 2015) In the report they highlight the CINT/Senior Scientific collaboration efforts. A feature is available on page 20 of the report. It can be viewed by clicking here.

Read the entire partnerships report (PDF - 40 Pages).

MD Anderson's Website Features our MRX Technology

(February 23, 2015) MD Anderson has created and published a link to its Magnetic Relaxometry Research Laboratory featuring our MRX II instrument and technology. The principal investigator is Dr. John D. Hazle, PhD, Professor & Chairman of the Imaging Physics Department at MD Anderson Cancer Center

To read the full article, follow the link below.

Senior Scientific is pleased to announce two new employees have joined Senior Scientific LLC.

(February 2, 2015)

Kayla Minser, M.S.,has joined our team as Biomedical Research Associate. Ms. Minser holds an M.S. in Biological Sciences from Purdue University, where she studied the mechanisms of breast cancer metastasis and methods by which to inhibit metastatic spread in vitro and in vivo. She will be supporting ongoing biological studies using functionalized nanoparticles in cell and animal models.

Andrew Gomez, M.S. has joined our team as a Process Development Engineer and lab manager. Mr. Gomez will soon receive his M.S. in Biomedical Engineering from the University of New Mexico, where he has been studying biologically inspired nanomaterials for drug delivery and monitoring in vivo. He will support nanoparticle production efforts for both commercial and internal R&D use.

Take a Nano Pill and Call Google in the Morning

(November 4, 2014) We are happy to report that Dr. Flynn is quoted in the article, "Take a Nano Pill and Call Google in the Morning?" published by TechNewsWorld. The article includes quotes from many prestigious researchers such as those at Quinnipiac University, Baruch College and the American Institute for Behavioral Research and Technology, so Dr. Flynn is positioned as an industry thought leader among stellar company!

To read the full article, follow the link below.

National Lab Day

(September 26, 2014) Chief Nanoparticle Chemist at Senior Scientific Dr. Erika Vreeland, presented our nanoparticle work at the National Lab Day in Washington: “How the National Labs Keep Moving America Forward”. She met and spoke with United States Secretary of Energy, Dr. Ernest Moniz.

To view images from the event, follow these links.

Film Created by the Los Alamos Labs for CINT Highlighting Collaborative Work by CINT and Senior Scientific

(June 12, 2014) This film was created by a film crew from the Los Alamos Laboratory to be part of the ongoing exhibit on nanotechnology at the Bradbury museum in Los Alamos for the Center for Integrative Nanotechnologies (CINT). It consists of interviews with Dr. Dale Huber and Edward R. Flynn which are partially overlaid visually by ongoing experiments and experimental results.

The beginning of the film consists of some of the early history of Dr. Flynn’s experience in biomagnetism which began the 90’s. Also shown is a large SQUID sensor for measuring magnetic fields from the brain using 155 SQUID sensors, along with some measurements of fields from the brain.

The historical content is followed by showing our own Leyma DeHaro recording data that is being taken on cancer cells using the magnetic relaxometry instrument and this is followed by the showing of confocal images of cancer cells.

The film also includes the analysis procedure for these cancer cells, showing the extraction of magnetic field contour lines from the data and the method the analysis code uses for multiple magnetic sources.

In addition, Senior Scientific’s Erika Vreeland is shown with the apparatus for making the magnetic nanoparticles at CINT and some of the results characterizing these nanoparticles including TEM images and size analysis.

Click to view video

The MRX II Has Landed

(June 11, 2014) The MRX II is up and running at MD Anderson! At the heart of the instrument are the multiple SQUID detectors working together to detect a signal from the bound nanoparticles in a sample. Based on the first generation system created by Ed Flynn himslef, the MRX II instrument includes new hardware and electronics to provide even better performance and seviceability in the field. The system, now in operation at MD Anderson, includes computer controlled mechanical stage movements , precisely milled platforms for sample positioning, and an integrated optical imaging capability, not to mention a professional exterior to match the high quality performance.

Link to full Update

PrecisionMRX Nanoparticle Production Process Ready

(April 14, 2014) Building upon local relationships, Senior Scientific is stepping into the commercial space with first product introductions through Azano Biotech. Azano currently supplies research reagents to the same cancer researchers who will eventually be customers for the MRX II instrument. Therefore, we are pleased to be making the PrecisionMRX Nanopartticles available for them to use is assays and applications that they will eventually want to quantify using our instrumentation. Azano is set up to take orders, package and distribute, as well as leverage existing relationships in the research community to whom we can introduce Precision MRX Nanoparticles.

Link to full Update

Progress on our First Major Product: the NanoMRX™ II

(March 19, 2014) The overarching mission for February has been to get the 9 Channel System up and running. We are delighted to be delivering this extraordinary device to our collaborators at MD Anderson. The full article can be found in the PDF version of this document. Please click below to view the file.

Link to full Update

Senior Scientific is pleased to announce two new employees have joined our team.

(December 11, 2013) Leyma De Haro, Ph.D., has joined Senior Scientific LLC as our Biomedical Applications Scientist. Ms. De Haro has a PhD in Biomedical Sciences from the University of New Mexico, and was most recently a Postdoctoral Research Scientist in the Bioscience Division of Los Alamos National Laboratories. She will be working with protocols for bioconjugation, in vitro assays, and preclinical in vivo measurements. She will be developing new applications inside Senior Scientific, and working in support of our initial external users.

Todor Karaulanov, Ph.D., has joined Senior Scientific LLC as our Chief Instrumentation Physicist. Mr. Karaulanov has a Ph.D. in Physics from the Bulgarian Academy of Sciences in Sofia, Bulgaria, and has worked as a Postdoctoral Scientist at Los Alamos National Laboratories and at the Univ. of California, Berkeley. He will be working all aspects of our instruments, including the present preclinical instruments and extensions to other platforms and clinical applications.

Manhattan Scientifics Announces Receipt of Second Milestone Payment for its Cancer Project

(October 1, 2013) Manhattan Scientifics, Inc. (the “Company”) closed the second tranche of financing in the amount of $500,000.The Company is on schedule with the instrument assembly and prove-ins set forth in the financing agreement.

Link to SEC 8K Filing

Magnetic Relaxometry with an Atomic Magnetometer & SQUID Sensors on Cancer Cells

(August 1, 2013) Magnetic relaxometry methods have been shown to be very sensitive in detecting cancer cells and other targeted diseases. Superconducting Quantum Interference Device (SQUID) sensors are one of the primary sensor systems used in this methodology because of their high sensitivity with demonstrated capabilities of detecting fewer than 100,000 magnetically-labeled cancer cells. The emerging technology of atomic magnetometers (AM) represents a new detection method for magnetic relaxometry with high sensitivity and without the requirement for cryogens. We report here on a study of magnetic relaxometry using both AM and SQUID sensors to detect cancer cells that are coated with superparamagnetic nanoparticles through antibody targeting. The AM studies conform closely to SQUID sensor results in the measurement of the magnetic decay characteristics following a magnetization pulse. The AM and SQUID sensor data are well described theoretically for superparamagnetic particles bound to cells and the results can be used to determine the number of cells in a cell culture or tumor. The observed fields and magnetic moments of cancer cells are linear with the number of cells over a very large range. The AM sensor demonstrates very high sensitivity for detecting magnetically labeled cells does not require cryogenic cooling and is relatively inexpensive.

Read the full publication

Bradbury Museum Features Dr.Flynn July 2013

(July 29, 2013) On July 26th 2013, the Los Alamos National Laboratory's Bradbury Science Museum opened a new exhibit on nanotechnology research, which featured, Senior Scientific and Dr. Edward R. Flynn’s work in early detection of cancer utilizing nanotechnology.